Euronext

Oxurion Receives Transparency Notification from Fidelity Management & Research Company LLC

Retrieved on: 
Friday, November 4, 2022
Company, Compliance, Sale, Diabetic retinopathy, Euronext, FMR, Severe cognitive impairment, Plasma kallikrein, Fidelity, DME, Patient, Pharmaceutical industry

Fidelity Management & Research Company LLC is controlled by FMR LLC.

Key Points: 
  • Fidelity Management & Research Company LLC is controlled by FMR LLC.
  • Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME.
  • Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties.
  • This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

Retrieved on: 
Friday, November 4, 2022
Disclosure, Company, Capital commitment, Compliance, Sale, EUR, Diabetic retinopathy, Group, Agreement, Euronext, SRS, Severe cognitive impairment, Plasma kallikrein, Cayman, USD, Capital, DME, Term Asset-Backed Securities Loan Facility, Patient, Pharmaceutical industry, Security (finance), Limited

Negma Group has converted 120 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase.

Key Points: 
  • Negma Group has converted 120 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 92,825,765 outstanding ordinary shares carrying voting rights (compared to 77,825,765 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.
  • Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties.

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Retrieved on: 
Friday, November 4, 2022
UC, CPK, Kidney disease, Lipid, Investigational New Drug, Investment, Saitama (city), Board, BCMA, FDA, D, CD, Safety, IND, Interferon, Fibrosis, SLE, Quality of life, CD19, RA, Intention, Rheumatoid arthritis, EULAR, Inflammatory bowel disease, CET, CEO, Filgotinib, JAK1, Gilead Sciences, Ulcerative colitis, NASDAQ, Jaki, Galapagos NV, Rheumatism, Union, Euronext, Psoriasis, Axial spondyloarthritis, Kidney, TYK2, JAK2, Patient, Renewable energy, Fine chemical, Pharmaceutical industry, Medical imaging, Vaccine, Dermatomyositis

Our renewed focus on two strategic therapeutic areas goes hand in hand with redirecting our resources.

Key Points: 
  • Our renewed focus on two strategic therapeutic areas goes hand in hand with redirecting our resources.
  • Aligned with our Vision 2028, we presented our financial outlook and capital allocation strategy at our R&D Day 2022.
  • We also presented our Vision 2028 roadmap for oncology at our R&D Day 2022.
  • Our first medicine for rheumatoid arthritis and ulcerative colitis is available in the European Union, Norway, Great Britain, and Japan.

Wolters Kluwer divestiture to proceed following Spanish regulatory clearance

Retrieved on: 
Thursday, November 3, 2022
ADR, Compliance, Wolters Kluwer, Accounting, Thomson Reuters, AEX, Risk, WKL, Karnov, Technology, American, Euronext Amsterdam, Solution, Security (finance), Euronext

November 3, 2022 Wolters Kluwer Legal & Regulatory announces today that the Spanish Antitrust Authority has given Karnov Group clearance to acquire the legal information assets of Wolters Kluwer and Thomson Reuters in Spain.

Key Points: 
  • November 3, 2022 Wolters Kluwer Legal & Regulatory announces today that the Spanish Antitrust Authority has given Karnov Group clearance to acquire the legal information assets of Wolters Kluwer and Thomson Reuters in Spain.
  • Therefore, the transaction announced on December 9, 2021, whereby Wolters Kluwer will divest its legal information units in France and Spain to Karnov can proceed.
  • The assets to be sold by Wolters Kluwer generated revenues of 85 million in 2021 (10% of Legal & Regulatory division revenues) and were profitable.
  • Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.

VEON publishes Q3 2022 trading update

Retrieved on: 
Thursday, November 3, 2022
Jazz, Bee line, EBITDA, Income, ARPU, Table, Failure, Annual report, Cyprus Securities and Exchange Commission, Headquarters, Churn, Acquisition, Technology, SEC, Capital expenditure, Company, Growth, Radio, Maus, Board, Weakness, Group, Forward-looking statement, Grammy Award for Best Country Performance by a Duo or Group with Vocal, G, Nasdaq, U.S. Securities and Exchange Commission, Note, United Kingdom, HQ, Sale, Risk, Government, Digital, COVID-19, VEON, Calendar, Yoy, Time, Safety, Telecommunication, USD, NASDAQ, Union, Achievement, Software, Euronext Amsterdam, Communication, Cryptocurrency, Bank, Mobile phone, Security (finance), Risk management, Helsi Herlinda, EU, Kyivstar, JazzCash, Djezzy, Euronext

Amsterdam, 3 November 2022 VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces a trading update for the third quarter and nine months ended 30 September 2022, including selected financial and operating results:

Key Points: 
  • Amsterdam, 3 November 2022 VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces a trading update for the third quarter and nine months ended 30 September 2022, including selected financial and operating results:
    In 3Q22, VEON recorded USD 2,077 million in total revenues, representing +3.6% YoY growth in reported currency (+3.4% YoY in local currency).
  • On 17 October 2022, VEON announced the appointment of Matthieu Galvani as Chief Corporate Affairs Officer.
  • Accordingly, such holders should not contact VEON Ltd.
    NASDAQ grants VEON extension until 3 April 2023 to comply with minimum share price requirement.
  • VEONs results presented in this trading update are, unless otherwise stated, based on IFRS and have not been externally reviewed and audited.

ING posts 3Q2022 net result of €979 million and announces additional distribution to shareholders

Retrieved on: 
Thursday, November 3, 2022
Annual report, Morning Star, Turnaround ADR, Sustainalytics, ESG, Risk, ING Group, International, Social, Internet, Legislation, ING, Sustainability, Lung compliance, New, Table, AA, COVID-19, Failure, FTSE Russell, Life, Biophysical environment, S&P Global Ratings, Union, Climate change, United, FATCA, MSCI, Rare-earth element, Risk management, EU, Euronext

ING is a global financial institution with a strong European base, oering banking services through its operating company ING Bank.

Key Points: 
  • ING is a global financial institution with a strong European base, oering banking services through its operating company ING Bank.
  • The purpose of ING Bank is empowering people to stay a step ahead in life and in business.
  • ING Banks more than 58,000 employees oer retail and wholesale banking services to customers in over 40 countries.
  • ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

ING announces change in Supervisory Board

Retrieved on: 
Thursday, November 3, 2022
Annual report, Morning Star, Turnaround ADR, Sustainalytics, ESG, Risk, ING Group, Social, Internet, Legislation, ING, Sustainability, Lung compliance, New, AA, COVID-19, Failure, FTSE Russell, Life, Biophysical environment, S&P Global Ratings, Union, Climate change, United, FATCA, MSCI, Rare-earth element, Risk management, EU, Euronext

ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank.

Key Points: 
  • ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank.
  • The purpose of ING Bank is empowering people to stay a step ahead in life and in business.
  • ING Banks more than 58,000 employees off er retail and wholesale banking services to customers in over 40 countries.
  • ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

ING announces share buyback programme of up to €1.5 billion

Retrieved on: 
Thursday, November 3, 2022
Annual report, Morning Star, Turnaround ADR, Sustainalytics, Risk, ESG, ING Group, Social, Internet, California Senate Bill 32, Legislation, ING, Sustainability, Lung compliance, New, AA, COVID-19, Failure, FTSE Russell, Life, Biophysical environment, S&P Global Ratings, Union, Climate change, United, FATCA, MSCI, Risk management, Euronext

ING is a global financial institution with a strong European base, oering banking services through its operating company ING Bank.

Key Points: 
  • ING is a global financial institution with a strong European base, oering banking services through its operating company ING Bank.
  • The purpose of ING Bank is: empowering people to stay a step ahead in life and in business.
  • ING Banks more than 58,000 employees oer retail and wholesale banking services to customers in over 40 countries.
  • ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

BenevolentAI to present at Jefferies Investor Conference in November

Retrieved on: 
Friday, November 4, 2022
Technology, Research, Clinical Trials, Health Technology, Software, Health, Pharmaceutical, Science, Artificial Intelligence, BAI, Probability, Benevolence, Research, AstraZeneca, Conference, Euronext, AMS, Euronext Amsterdam, Pharmaceutical industry

BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate at the upcoming Jefferies London Healthcare Conference from 15-17 November.

Key Points: 
  • BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate at the upcoming Jefferies London Healthcare Conference from 15-17 November.
  • Nick Keher, Chief Financial Officer of BenevolentAI is scheduled to present at 10.20 AM GMT on Thursday, 17 November 2022.
  • BenevolentAIs management, investor relations and business development team will be attending and available throughout the conference for meetings.
  • BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange.

Solvay and Orbia Join Forces to Create a Joint Venture in North America to Supply Critical Materials to the Battery Market

Retrieved on: 
Thursday, November 3, 2022
Technology, Automotive, Mining, Minerals, General Automotive, Natural Resources, Other Energy, Other Manufacturing, Utilities, Semiconductor, Alternative Energy, Engineering, Energy, Chemicals, Plastics, Automotive Manufacturing, Telecommunications, Manufacturing, Networks, Ministry of Energy, Investment, City, Polymer solution casting, Southeastern United States, Solution, Precision agriculture, Water, Netafim, Safety, Department, U.S. Department of Energy, Office of Inspector General, Group, Euronext, CEO, Lithium hexafluorophosphate, Food, Climate, Hydrofluoric acid, VCM, U.S. Department of Defense Strategy for Operating in Cyberspace, Plant, Chlorine, Partnership, Health, Technology, Fluorine, Efficiency, Thermoplastic, Renewable energy, Chemical, PVDF, Orbia, Energy

Solvay and Orbia today announced their entry into a joint venture framework agreement to create a partnership for the production of suspension-grade polyvinylidene fluoride (PVDF), creating the largest capacity in North America.

Key Points: 
  • Solvay and Orbia today announced their entry into a joint venture framework agreement to create a partnership for the production of suspension-grade polyvinylidene fluoride (PVDF), creating the largest capacity in North America.
  • The Solvay-Orbia joint venture would fill a significant supply gap and will build upon favorable regulatory conditions promoting regional production and material security.
  • Solvay, a global leader in PVDF, brings process technology and unparalleled global market know-how to this venture.
  • We are delighted to partner with Orbia on this exciting opportunity to expand our battery solutions into North America, with strong support by the U.S. Department of Energy, said Ilham Kadri, CEO of Solvay.